Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial

Sylvie Giacchetti; Enora Laas; Thomas Bachelot; Jérôme Lemonnier; Fabrice André; David Cameron; Judith M. Bliss; Sylvie Chabaud; Anne-Claire Hardy- Bessard; Magali Lacroix‐Triki; Jean-Luc Canon; Marc Debled; Mario Campone; Paul Cottu; Florence Dalenc; Annabelle Ballesta; Frédérique Penault‐Llorca; Bernard Asselain; Élise Dumas; Fabien Reyal; Paul Gougis; Francis Lévi; Anne‐Sophie Hamy

doi:10.1016/j.ebiom.2024.105141

Abstract

Circadian rhythms regulate cellular physiology and could influence the efficacy of endocrine therapy (ET) in breast cancer (BC). We prospectively tested this hypothesis within the UNIRAD adjuvant phase III trial (NCT01805271).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Giacchetti et al. (2024) studied this question.

synapsesocial.com/papers/68e6b291b6db643587633d0b https://doi.org/10.1016/j.ebiom.2024.105141

View Full Paper

Ask AI

Bookmark

Share

Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial

Abstract

Discussion

Cite This Study

Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading